New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice
September 09 2020 - 6:33AM
Business Wire
Preclinical study at Emory University explores relationship
between cellular NAD+ and retinal damage
ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical
research published in Investigative Ophthalmology & Visual
Science finding Niagen® (patented nicotinamide riboside, or NR)
prevented light-induced retinal damage in mice. This research paves
the way for future preclinical and clinical studies exploring the
relationship between NAD+ levels and preservation of long-term
ocular health. The study, conducted through the ChromaDex External
Research Program (CERP), was led by Jeffrey H. Boatright, PhD,
FARVO, Professor of Ophthalmology and principal investigator at
Emory University and the Atlanta VA Center for Visual and
Neurocognitive Rehabilitation.
In previously published preclinical models, age-related declines
in ocular health have been associated with low levels of NAD+, an
important coenzyme that helps power metabolically active cells and
tissues. NAD+ levels naturally decline with age as well as from
environmental stressors. These declines in NAD+ may be at the heart
of degeneration of the retina, the ocular tissue responsible for
vision, and the subsequent vision loss that ensues with aging.
“We are encouraged by these findings of protective effects of
nicotinamide riboside in this retinal degeneration mouse model. The
research also fired the imaginations of two trainees in my lab,
Xian Zhang, MD and Nate Henneman, and is a significant step in
their professional development,” says Dr. Boatright. “We look
forward to furthering this research in humans to see how NR may
support long-term ocular health.”
ChromaDex’s Niagen had already been proven in nine published
studies to raise levels of NAD+ in the human body. The researchers
in this latest study explored how augmenting NAD+ levels affected
the function and viability of retinal cells in mice following
exposure to damaging light. This light was meant to simulate the
decades of UV light exposure that the retina endures over a
lifetime.
The researchers found that exposure to the damaging light
significantly depressed retinal NAD+ levels. They also observed
that, compared to control mice, mice given Niagen the day before
and morning before light exposure had higher retinal NAD+ levels,
thicker retinas, fewer dying (apoptotic) retinal cells, and less
retinal inflammation following the light damage.
This study contributes to a growing body of evidence in
preclinical models for Niagen’s role in supporting metabolically
active tissues, like the retina, against age-related and
environmental stressors.
“Just this year, we’ve seen numerous studies published on the
benefits of Niagen in human, animal, and cell models,” says Dr.
Andrew Shao, ChromaDex Senior Vice President of Global Scientific
& Regulatory Affairs. “This study paves the way for future
research in humans studying age-related declines in ocular health
which is a major public health problem.”
ChromaDex, the exclusive licensee of Dr. Charles Brenner’s
patented NR, has invested over $35 million in investigating,
manufacturing and offering NR in the form of Niagen and has secured
more than 20 patents. ChromaDex has demonstrated the safety and
efficacy of Niagen in eleven published human trials (and over 20
additional ongoing studies further evaluating its safety and
efficacy) and has achieved government regulatory acceptance in the
United States, Canada, the European Union, and Australia.
For additional information on ChromaDex, please visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a science-based integrated nutraceutical
company devoted to improving the way people age. ChromaDex
scientists partner with leading universities and research
institutions worldwide to discover, develop and create solutions to
deliver the full potential of NAD and its impact on human health.
Its flagship ingredient, NIAGEN® nicotinamide riboside, sold
directly to consumers as TRU NIAGEN®, is backed with clinical and
scientific research, as well as extensive IP protection. TRU
NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a
website at www.chromadex.com to which ChromaDex regularly posts
copies of its press releases as well as additional and financial
information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to Niagen and the prevention
of light-induced retinal damage in mice and the relationship
between Niagen, NAD+ levels and preservation of long-term ocular
health. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2019 as amended, ChromaDex's
Quarterly Reports on Form 10-Q and other filings submitted by
ChromaDex to the SEC, copies of which may be obtained from the
SEC's website at www.sec.gov. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200909005235/en/
ChromaDex Media Contact: Alex Worsham, Senior Director of
Global Corporate Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of FP&A and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024